The current financial score of Immunic Inc is 7.02. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Immunic Inc is 9.17. Its current P/E ratio is -0.64, which is -53.82% below the recent high of -0.30 and -2572.78% above the recent low of -17.22.
The current earnings forecast score of Immunic Inc is 9.17. The average price target is 43.09, with a high of 85.00 and a low of 22.00.
The current price momentum score of Immunic Inc is 5.60. Currently, the stock price is trading between the resistance level at 14.26 and the support level at 6.93, making it suitable for range-bound swing trading.
The current institutional shareholding score of Immunic Inc is 5.00. The latest institutional shareholding proportion is 57.65%, representing a quarter-over-quarter increase of 17.63%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
No risk assessment score is currently available for Immunic Inc. The Biotechnology & Medical Research industry's average is 3.94. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.